Acute application of cisplatin affects methylation status in neuroblastoma cells

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1655-1660

  Tabata, Keiichi ^a   Sakai, Hayato ^a   Nakajima, Ryosuke ^a   Saya Nishemura, Reiko ^a   Motani, Kou ^a   Okano, Soichiro ^b   Shibata, Yasuko ^b   Abiko, Yoshimtsu ^b   Suzuki, Takashi ^a  

^a NIHON UNIVERSITY   (Japan)

^b School of Dentistry at Matsudo   (France)

Author keywords

Cisplatin; Methylation; Neuroblastoma; Proteomics

Indexed keywords

ADENOSYLHOMOCYSTEINASE; ARGININE SERINE RICH 3 SPLICING FACTOR; BETA ACTIN; CHAPERONIN CONTAINING TCP1; CHAPERONIN CONTAINING TCP1 BETA SUBUNIT; CISPLATIN; ELONGATION FACTOR 1; ELONGATION FACTOR 1GAMMA; HISTONE; HISTONE H3K9; PROTEOME; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN IMR 32; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HISTONE METHYLATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; UPREGULATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NEUROBLASTOMA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79954565840     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1222     Document Type: Article

References (22)

1. Berthold F: Overview: biology of neuroblastoma. In: Neuroblastoma: Tumor Biology and Therapy. Pochedly C (ed). CRC Press Inc., Boca Raton, pp1-27, 1990.
2. Keshelava N, Seeger RC, Groshen S and Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405, 1998. (Pubitemid 28551122)
3. Dhooge CRM, De Moerloose BMJ, Benoit YCM, Roy NV, Philippé J and Laureys GGM: Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer 80: 1250-1257, 1997. (Pubitemid 27407225)
4. Munoz M, Henderson M, Haber M and Norris M: Role of the MRP1/ABCC1 multidrug transpoter protein in cancer. EUBMB Life 59: 752-757, 2007. (Pubitemid 351412076)
5. Keshelava N, Zuo JJ, Chen P, et al: Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61: 6185-6193, 2001. (Pubitemid 32768583)
6. Qiu YY, Mirkin BL and Dwivedi RS: Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev 29: 456-463, 2005. (Pubitemid 41406141)
7. Fuluda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B and Debatin KM: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865-5877, 2001. (Pubitemid 32937956)
8. Teitz T, Lahti JM and Kidd J: Aggressive childhood neuroblastoma do not express caspase-8: an important component of programmed cell death. J Mol Med 79: 428-436, 2001. (Pubitemid 32757468)
9. Okano S, Shibata Y, Shiroza T and Abiko Y: Proteomics-based analysis of a counter-oxidatrve stress system in Porphyromonas gingivalis. Proteomics 6: 251-258, 2006. (Pubitemid 43142949)
10. Ingrosso D and Perna AF: Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochim Biophys Acta 1790: 892-899, 2009.
11. van Noesel MM and Versteeg R: Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre'. Gene 325: 1-15, 2004.
12. Koul S, McKiernan JM, Narayan G, et al: Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 3: 16, 2004.
13. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP and Pogribny IP: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 6: 1089-1098, 2007. (Pubitemid 46554580)
14. Abbosh PH, Montgomery JS, Starkey JA, et al: Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66: 5582-5591, 2006. (Pubitemid 43927108)
15. Vandromme M, Chailleux C, Escaffit F and Trouche D: Binding of the retinoblastoma protein is not the determinant for stable repression of some E2F-regulated promoters in muscle cells. Mol Cancer Res 6: 418-425, 2008. (Pubitemid 351416532)
16. Zinn RL, Pruitt K, Eguchi S, Baylin SB and Herman JG: hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 67: 194-201, 2007. (Pubitemid 46142775)
17. Zhao W, Soejima H, Higashimoto K, et al: The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 137: 431-440, 2005. (Pubitemid 40628452)
18. Chen H, Yan Y, Davidson TL, Shinkai Y and Costa M: Hypoxic stress induces dimethylated histone H3 Lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 66: 9009-9016, 2006. (Pubitemid 44521119)
19. Chen H, Ke Q, Kluz T, Yan Y and Costa M: Nickel ions increase histone H3 Lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol 26: 3728-3737, 2006. (Pubitemid 43726391)
20. Qiu YY, Mirkin BL and Dwivedi RS: Differential expression of DNA-methyl transferase in drug resistant murine neuroblastoma cells. Cancer Detect Prev 26: 444-453, 2002. (Pubitemid 36035374)
21. Grantham J, Brackley KI and Willison KR: Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp Cell Res 312: 2309-2324, 2006. (Pubitemid 43928947)
22. Yokota S, Yanagi H, Yura T and Kubota H: Cytosolic chaperonin-containing t-complex polypeptide 1 changes the content of a particular subunit species concomitant with substrate binding and folding activities during the cell cycle. Eur J Biochem 268: 4664-4673, 2001. (Pubitemid 34203415)